| 伊立替康联合卡培他滨治疗晚期胃癌疗效分析 |
| |
| 引用本文： | 刘剑.伊立替康联合卡培他滨治疗晚期胃癌疗效分析[J].肿瘤基础与临床,2011,24(1):17-18. |
| |
| 作者姓名： | 刘剑 |
| |
| 作者单位： | 海安县人民医院肿瘤科,江苏,南通,226601 |
| |
| 摘 要： | 目的 观察伊立替康联合卡培他滨治疗晚期胃癌的疗效和毒副反应.方法 全组24例胃癌均接受化疔.具体方案:伊立替康180 mg/m<'2>,静脉滴注,d<,1>;卡培他滨1 650 mg/(m<'2>·d),口服,d<,1～5>.14 d为1个周期,4个周期后评价疗效和毒副反应.结果 全组24例中,CR 1例,PR 8例,...
|
| 关 键 词： | 晚期胃癌 伊立替康 卡培他滨 |
The Analysis of Curative Efficacy of Irinotecan Combined with Capecitabine in the Treatment of Advanced Gastric Cancer |
| |
| Liu Jian.The Analysis of Curative Efficacy of Irinotecan Combined with Capecitabine in the Treatment of Advanced Gastric Cancer[J].journal of basic and clinical oncology,2011,24(1):17-18. |
| |
| Authors: | Liu Jian |
| |
| Institution: | Liu Jian(Department of Oncology,the People′s Hospital of Hai′an,Nantong 226601,China) |
| |
| Abstract: | Objective To investigate the efficacy and toxicities of irinotecan combined with capecitabine in the treatment of patients with advanced gastric cancer. MethodsAll the 24 patients received the chemotherapy.The regimen:irinotecan 180 mg/m2,d1;capecitabine 1 650 mg/(m2·d),d1-5.Every 14 days were 1 cycle.The efficacy and toxicities were evaluated after 4 cycles of chemotherapy. ResultsAmong the 26 cases,CR 1 case,PR 8 cases,SD 7 cases,PD 8 cases,the total effective rate was 37.5%,the disease control rate was 66.7%.The median time to progression was 5.8 months,the median survival time was 10.6 months.The main toxicities were delayed diarrhea,myelosuppression,nausea and vomiting. ConclusionThe irinotecan and capecitabine can be effective for the patients with advanced gastric cancer.Its toxicities can be tolerated. |
| |
| Keywords: | advanced gastric cancer irinotecan capecitabine |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
